Dr. Geoffrey R. Oxnard on When to Change EGFR TKIs

November 14, 2015
Geoffrey R. Oxnard, MD

Special Reports, NSCLC (Issue 9), Volume 9, Issue 4

Geoffrey R. Oxnard, MD, Assistant Professor of Medicine, Harvard Medical School, talks about the treatment options for patients with lung cancer who have become resistant to their first-line treatments.

Geoffrey R. Oxnard, MD, Assistant Professor of Medicine, Harvard Medical School, talks about the treatment options for patients with lung cancer who have become resistant to their first-line treatments.

Oxnard says the standard of care is chemotherapy with pemetrexed and platinum based on the IMPRESS trial, which showed a response rate of 32% and a profession-free survival rate (PFS) of 5 to 6 months. He adds that other options for patients are now available, such as afatinib which has a response rate of around 10% and a PFS of about 3 months.

Oxnard also says emerging EGFR inhibitors such as rociletinib and osimertinib could be options for patients as well, depending on the situation.